COMMUNIQUÉS West-GlobeNewswire

US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam
12/10/2018
LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious [...]
Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™
12/10/2018
LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious [...]
Exagen Announces Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus
12/10/2018
Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests ALBUQUERQUE, NM and SAN DIEGO, CA, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life [...]
Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018
12/10/2018
WALTHAM, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018. The Company will host a conference [...]
MPX Expands Maryland Footprint With Opening of Baltimore Dispensary
12/10/2018
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“ MPX ” or the “ Company ”) (CSE: MPX; OTC: MPXEF) today announced that it opened its new Health for Life dispensary in Baltimore, Maryland which [...]
MRI Interventions and Monteris Medical Announce Collaboration to Develop Next-Generation Head Fixation Frames for Laser Ablation Neurosurgery
12/10/2018
IRVINE, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) and Monteris Medical, Inc. today announced a collaborative co-development agreement to provide a next-generation head fixation frame [...]
Equillium Announces Pricing of Initial Public Offering
12/10/2018
LA JOLLA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory [...]
Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis
12/10/2018
Scythian’s Chief Medical Officer, The Famed Dr. Barnes, Receives National Praise for His Advocacy, Education and Tireless Leadership from Government, Media and Medical Organizations to Assist in Making This Major Event [...]
Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
12/10/2018
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and [...]
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
12/10/2018
SAN CARLOS, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating [...]
Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018
12/10/2018
Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health [...]
Emblem to supply British Columbia and Saskatchewan markets with high quality cannabis
12/10/2018
Emblem supply to reach four key provinces TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF ) (“Emblem” or the "Company") today announced that its wholly-owned subsidiary, Emblem Cannabis [...]
Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation
12/10/2018
LANGHORNE, Pa. and SAN FRANCISCO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) and Adynxx, Inc., a privately held biopharmaceutical company, today announced that they have entered into a [...]
Axsome Therapeutics to Present at Upcoming Investor Conferences
12/10/2018
NEW YORK, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies
12/10/2018
To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution PHOENIX, Oct. 12, 2018 (GLOBE NEWSWIRE) -- [...]
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia
12/10/2018
CAMBRIDGE, Mass. and BEIJING, China, Oct. 12, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China
12/10/2018
NEW YORK and MELBOURNE, Australia, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic [...]
Ossur Hf : Q3 2018 Results - Conference call Thursday 25 October at 11:00 CET
12/10/2018
Announcement no. 60/2018 12 October 2018 Conference call on Thursday 25 October at 11:00 CET / 9:00 GMT / 5:00 EDT Össur will publish its financial results for Q3 2018 prior to market opening on Thursday 25 October. [...]
Fiasp® is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart
12/10/2018
Hyderabad, India, 12 October 2018 - For children and adolescents (1 to <18 years old) living with type 1 diabetes, Fiasp ® (an ultra-fast acting formulation of insulin aspart) could be an option to better manage [...]

Pages